| 1 |
Pan X, Xu J, Ren H, et al. Changing spectrum of biopsy-proven primary glomerular diseases over the past 15 years: a single-center study in China [J]. Contrib Nephrol, 2013, 181: 22-30.
|
| 2 |
Hofstra JM, Wetzels JF. Management of patients with membranous nephropathy [J]. Nephrol Dial Transplant, 2012, 27(1): 6-9.
|
| 3 |
Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy [J]. N Engl J Med, 1993, 329(2): 85-89.
|
| 4 |
KDIGO Clinical Practice Guideline for Glomerulonephritis[EB/OL].
URL
|
| 5 |
吴燕，左科，王波，等．激素联合环磷酰胺治疗特发性膜性肾病前瞻性对照性临床观察[J]．肾脏病与透析肾移植杂志，2012，21(2): 109-114.
|
| 6 |
Yuan J, Fang W, Zhang W, et al. Treatment of nephrotic idiopathic membranous nephropathy with monthly i．v. pulse cyclophosphamide and oral steroids: a single centre′s retrospective study [J]. Nephrology (Carlton), 2011, 16(4): 440-445.
|
| 7 |
李舒，王玲，张敏芳，等．环磷酰胺联合糖皮质激素治疗特发性膜性肾病的疗效和预测因素分析[J]．中华肾脏病杂志，2015，31(11): 801-810.
|
| 8 |
解放军肾脏病研究所学术委员会．特发性膜性肾病的诊断及治疗规范[J]．肾脏病与透析肾移植杂志，2004，13(6): 558-559.
|
| 9 |
Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy [J]. N Engl J Med, 1984, 310(15): 946-950.
|
| 10 |
Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy [J]. N Engl J Med, 1989, 320(1): 8-13.
|
| 11 |
Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy [J]. Kidney Int, 1995, 48(5): 1600-1604.
|
| 12 |
Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy [J]. J Am Soc Nephrol, 1998, 9(3): 444-450.
|
| 13 |
Chen Y, Schieppati A, Cai G. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials [J]. Clin J Am Soc Nephrol, 2013, 8(5): 787-796.
|
| 14 |
Xie G, Xu J, Ye C, et al. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults [J]. PLoS One, 2012, 7(9): e44330.
|
| 15 |
Xu J, Zhang W, Xu Y, et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial [J]. Contrib Nephrol, 2013, 181: 152-162.
|
| 16 |
Busch M, Rüster C, Schinköthe C, et al. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy [J]. Clin Nephrol, 2013, 80(2): 105-113.
|
| 17 |
Fervenza FC, Canetta PA, Barbour SJ, et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR)[J]. Nephron, 2015, 130(3): 159-168.
|
| 18 |
Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide [J]. Am J Kidney Dis, 2007, 50(2): 248-256.
|
| 19 |
Yang S, Xie L, Xue W, et al. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety[J]. Nephrology (Carlton), 2013, 18(9): 615-622.
|
| 20 |
Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy [J]. Nephrol Dial Transplant, 2014, 29(8): 1570-1577.
|